Key Points {#FPar1}
==========

Most safety signals regarding asthma therapy in children are known, but we identified several new signals that need to be explored further.Lack of stratification by age and sex may mask safety signals in children.

Introduction {#Sec1}
============

Asthma drugs are one of the most frequently used drugs in children, with approximately 21% of children aged 2--11 years using asthma medication \[[@CR1], [@CR2]\]. Since asthma is a chronic disease, this medication may be used for many years \[[@CR3]\]. Like any drug, asthma medication may cause adverse reactions. Randomized controlled trials (RCTs) are the gold standard to investigate the efficacy of drugs but are limited in size and follow-up and therefore can only detect events that occur frequently and may miss rare or long-term side effects. Children remain underrepresented in RCTs, even though attempts have been made to increase these numbers, including the Paediatric Regulation that came into force in the EU in 2007 \[[@CR4]--[@CR7]\]. Given the lack of data, medication---including asthma drugs---is often not authorised for use in children, leading to substantial off-label use \[[@CR8]\]. This is concerning because the efficacy and safety profile of drugs might differ between children and adults \[[@CR9]\]. The risk assessment of drugs does not stop after market authorisation but should be monitored throughout the lifecycle of the drug \[[@CR10]\]. Clearly, more child-specific safety and efficacy information on asthma drugs is needed, something the European Medicines Agency (EMA) emphasises \[[@CR11]\].

Spontaneous report databases are an important source of safety information, and in fact remain the most frequent source from which regulatory action is initiated \[[@CR12]\]. They cover large source populations, including special populations such as children, and may have more power to detect rare signals than mining of electronic healthcare records \[[@CR13]--[@CR15]\]. The EMA defines an adverse drug reaction as "a response to a medicinal product which is noxious and unintended" \[[@CR16]\]. Spontaneous reports only contain information on the event and the drug of interest, not on the non-exposed events or exposure without events, so cannot be used to measure incidence rates. However, signal detection based on disproportionality analyses is still possible \[[@CR15], [@CR17], [@CR18]\]. Since the risk of adverse events can be age specific, stratification of these analyses is recommended \[[@CR19]\]. A previous study using EudraVigilance, the European database for suspected adverse reactions, characterised spontaneous reports of asthma drugs in children over the study period 2007--2011 \[[@CR20]\]. The authors could not identify new signals in relation to asthma drugs, potentially because of low numbers. In this study, we aimed to investigate the safety of asthma drugs in children in EudraVigilance in the period 2011--2017. The objective of this study was to provide an overview of safety signals associated with asthma drugs in children and to identify new signals in the EudraVigilance database.

Methods {#Sec2}
=======

Database {#Sec3}
--------

We used the EudraVigilance database, which is developed and maintained by the EMA to collect reports of suspected adverse reactions. It contains adverse events reported in relation to any drug authorised or being studied in the European economic area. EudraVigilance contains spontaneous reports from healthcare professionals, patients and marketing authorisation holders and clinical trial safety data dating back to 1995. The number of new reports in this database increases each year, with 1,238,178 reports of adverse events collected in 2016 \[[@CR21]\]. Events are coded using the Medical Dictionary for Regulatory Activities (MedDRA). For this study, information on the frequency of MedDRA (version 20.1) 'high-level terms' in spontaneous reports regarding asthma drugs was obtained. These terms are grouped by 'system organ classes' (SOCs), for example, by aetiology ('infections and infestations') or manifestation site ('respiratory, thoracic and mediastinal disorders') \[[@CR22]\]. Drugs are coded by anatomical therapeutic chemical (ATC) classification.

Data Selection {#Sec4}
--------------

All spontaneous reports submitted to EudraVigilance between 1 January 2011 and 1 January 2017 and concerning 24 asthma drugs were analysed. Reports concerning suspect or interacting single drugs or fixed-dose combinations from the following drug classes were included: β~2~-adrenergic receptor agonists, inhaled corticosteroids (ICS), muscarinic receptor antagonist, chromones, xanthines, leukotriene receptor antagonists (LTRAs) and anti-immunoglobulin E (IgE) drugs (Table [1](#Tab1){ref-type="table"}). Counts of spontaneous reports were provided for the whole paediatric group, by sex, by age category (0--2, 3--11 and 12--17 years) and for adults. Reports that did not include the patient's age were excluded. To calculate the measure of disproportionality, the background frequencies of adverse events for all drugs were also included in the data files. The free text narrative from the reports was not available because of data protection regulations. The retrieved data were at the group level only and included non-identifiable patient data, so no ethics review board approval was required.Table 1Number of reports per drug in childrenATC codeDrug nameAdministrationDrug classReports (*N*)R03DC03MontelukastOralLTRA2210R03AC02SalbutamolInhaledSABA947R03DX05OmalizumabSubcutaneousMonoclonal antibody690R03CC02Salbutamol, systemicOral, intravenousSABA676R03BA02BudesonideInhaledICS584R03AK06Salmeterol + fluticasoneInhaledLABA + ICS565R03BA05FluticasoneInhaledICS391R03BA01BeclomethasoneInhaledICS169R03AK07Formoterol + budesonideInhaledLABA + ICS161R03DA04TheophyllineOral, intravenousXanthine98R03CC03Terbutaline, systemicOral, intravenousSABA87R03BB01Ipratropium bromideInhaledSAMA85R03AC13FormoterolInhaledLABA80R03AC03TerbutalineInhaledSABA73R03BA08CiclesonideInhaledICS36R03BC01Cromoglicic acidInhaledChromones34R03AC12SalmeterolInhaledLABA32R03BA07MometasoneInhaledICS31R03DC01ZafirlukastOralLTRA29R03AL01Fenoterol and ipratropium bromideInhaledLABA + SAMA24R03AL02Salbutamol and ipratropium bromideInhaledSABA + SAMA21R03AK10Vilanterol and fluticasone furoateInhaledLABA + ICS16R03BB04Tiotropium bromideInhaledLAMA9R03AK11Formoterol and fluticasoneInhaledLABA + ICS3*ATC* anatomical therapeutic chemical, *ICS* inhaled corticosteroids, *LABA* long-acting β-agonist, *LAMA* long-acting muscarinic antagonist, *LTRA* leukotriene receptor antagonist, *SABA* short-acting β-agonist, *SAMA* short-acting muscarinic antagonist

Signal Detection {#Sec5}
----------------

As one report may contain multiple drugs and/or multiple adverse events, we defined the combination of one drug and one event as drug--event combinations (DECs). To identify signals, we calculated the disproportionality in reporting using the proportional reporting ratio (PRR), defined as the proportion of the event of interest for a specific drug, with the comparator being the proportion of the event of interest for all other drugs from the database (other asthma and non-asthma drugs) \[[@CR23]\]. The PRR was calculated only if a DEC was reported at least five times. We also calculated 95% confidence intervals (CIs), and the criterion for a signal was a lower bound higher than one (PRR025 \> 1) \[[@CR19], [@CR24]--[@CR26]\]. We first calculated the PRR in reports concerning children only, then in the whole dataset including children and adults to examine masking of safety signals if stratification for children had not been done. We also repeated the analyses of paediatric reports while stratifying for age and sex \[[@CR17]\]. Finally, we calculated another measurement of disproportionality---the PRR by therapeutic area (PRR-TA)---for paediatric reports. For this calculation, only reports related to asthma drugs for other events were used as the comparator. The PRR-TA has been proposed in the literature as a method to eliminate false signals due to confounding by indication \[[@CR27]\].

Definition of New Signals {#Sec6}
-------------------------

To identify already known signals, we searched the safety information as documented in the summary of product characteristics (SmPC). If the event was not listed in the SmPC, we also searched UpToDate and Martindale \[[@CR28]\]. UpToDate is a widely used point-of-care clinical tool to support decision making that includes summaries of the current available evidence on medication, including possible adverse events \[[@CR29]--[@CR31]\]. Martindale is an online drug database published by the Pharmaceutical Press and is updated every 3 months \[[@CR32]\]. If an adverse event was not mentioned by any of these sources, we considered the signal on this adverse event to be a new signal.

Results {#Sec7}
=======

From January 2011 to January 2017, a total of 372,345 spontaneous reports on adverse events in children and 3,182,083 in adults were reported to EudraVigilance. From these reports, we identified 21,264 asthma medication-related DECs in children and 172,035 in adults for the same drugs. The asthma drug most often included in reports in children was montelukast (2210 reports), followed by inhaled salbutamol (947) and anti-IgE (omalizumab, 690) (Table [1](#Tab1){ref-type="table"}). We identified 3697 unique DECs, 385 of which met the criteria of a safety signal in children. All safety signals and corresponding SOCs are listed in the Electronic Supplementary Material (ESM) 1. Signals were mainly related to the SOCs 'psychiatric disorders' (*n* = 65), 'respiratory, thoracic and mediastinal disorders' (*n* = 56) and 'nervous system disorders' (*n* = 29) (Fig. [1](#Fig1){ref-type="fig"}). Signals also often related to 'Injury, poisoning and procedural complications' (*n* = 49), which included for example 'off-label uses' and 'accidental exposure to product'. We identified 31 signals of psychiatric adverse events in combination with montelukast, which also included the five most frequently reported DECs (Table [2](#Tab2){ref-type="table"}). The highest PRR in children was for the association between montelukast use and 'vasculitides' (PRR 90.7; 95% CI 46.3--177.9; 13 reports), followed by fluticasone and 'adrenal cortical hypofunctions' (PRR 59.5; 95% CI 39.1--90.4; 22 reports) (Table [3](#Tab3){ref-type="table"}). All ten signals with the highest PRR were already known.Fig. 1Signals in children categorized as to whether it remains a signal in the whole dataset (children and adults)Table 2Drug--event combinations of montelukast and psychiatric eventsReaction HLTReports (*N*)PRR (95% CI)Behaviour and socialisation disturbances32816.0 (14.4--17.8)Parasomnias25249.5 (43.3--56.6)Anxiety symptoms2496.4 (5.7--7.2)Emotional and mood disturbances NEC2476.9 (6.1--7.7)Suicidal and self-injurious behaviour2197.1 (6.3--8.1)Abnormal behaviour NEC2119.7 (8.5--11.1)Disturbances in initiating and maintaining sleep16310.4 (8.9--12.1)Depressive disorders14210.2 (8.6--12.0)Fear symptoms and phobic disorders (including social phobia)7227.5 (21.5--35.1)Mood alterations with depressive symptoms678.0 (6.3--10.2)Sleep disorders NEC667.0 (5.5--9.0)Increased physical activity levels633.4 (2.7--4.3)Speech articulation and rhythm disturbances616.3 (4.9--8.1)Fluctuating mood symptoms5920.6 (15.8--26.9)Attention deficit and disruptive behaviour disorders3314.8 (10.4--21.0)Tic disorders328.1 (5.7--11.5)Mood disorders NEC322.5 (1.7--3.5)Obsessive-compulsive disorders and symptoms3214.8 (10.4--21.3)Panic attacks and disorders3010.7 (7.4--15.5)Thinking disturbances2815.4 (10.5--22.7)Confusion and disorientation252.0 (1.3--2.9)Sleep disturbances NEC224.6 (3.0--7.0)Affect alterations NEC219.3 (6.0--14.4)Personality disorders NEC2023.3 (14.6--37.1)Psychotic disorder NEC183.2 (2.0--5.1)Educational issues1826.0 (15.8--42.6)Psychiatric elimination disorders1712.7 (7.8--20.8)Criminal activity1212.4 (6.9--22.3)Anxiety disorders NEC1014.8 (7.8--28.3)Stereotypies and automatisms94.4 (2.3--8.5)Impulse control disorders76.1 (2.9--12.9)*CI* confidence interval, *HLT* high-level term, *NEC* not elsewhere classified, *PRR* proportional reporting ratioTable 3Top ten strongest signalsNameReaction HLTReports (*N)*PRR (95% CI)MontelukastParasomnias25249.5 (43.3--56.6)Salmeterol + fluticasoneAdrenal cortical hypofunctions3057.4 (39.9--82.6)FluticasoneAdrenal cortical hypofunctions2259.5 (39.1--90.4)BudesonideAdrenal cortical hypofunctions2239.8 (26.1--60.7)BudesonideCataract conditions1758.5 (35.8--95.5)MontelukastVasculitides1390.7 (46.3--177.9)Salbutamol, inhaledThermal burns1335.4 (20.1--62.2)Salmeterol + fluticasoneGlaucomas (excluding congenital)934.0 (17.5--66.2)FluticasoneCataract conditions734.1(16.2--72.1)FluticasoneDental and periodontal infections and inflammations546.2 (18.9--112.7)*CI* confidence interval, *HLT* high-level term

New Signals {#Sec8}
-----------

Most of the 385 signals in children were already known and thus described in the SmPC, UpToDate and/or Martindale; only 30 were classified as new. New signals most often concerned omalizumab, with seven new signals, followed by the fixed combination of salmeterol and fluticasone (six new signals) and montelukast (five new signals) (Table [4](#Tab4){ref-type="table"}). See the ESM for a table presenting all signals not described in the SmPC but mentioned in UpToDate and/or Martindale.Table 4All new signals by drugReaction HLTReportsPRR (95% CI)PRR-TA (95% CI)SOCBudesonide Leukopenias NEC83.5 (1.7--6.9)14.8 (5.1--42.4)Immune system disorders Hypertrichoses517.8 (7.3--43.1)11.1 (3.2--38.1)Skin and subcutaneous disordersFluticasone Dyskinesias and movement disorders NEC132.3 (1.3--3.9)1.3 (0.7--2.2)Nervous system disorders Mental impairment (excluding dementia and memory loss)52.8 (1.2--6.6)1.3 (0.5--3.2)Nervous system disorders Hypoglycaemic conditions NEC52.9 (1.2--7.1)2.7 (1.0--6.8)Metabolism and nutrition disordersIpratropium bromide Tremor (excluding congenital)66.6 (3.1--14.3)2.2 (1.0--4.7)Nervous system disordersMontelukast Paraesthesias and dysaesthesias432.0 (1.5--2.7)1.5 (1.0--2.2)Nervous system disorders Skin injuries NEC152.2 (1.3--3.7)1.8 (0.9--3.6)Skin and subcutaneous disorders Eyelid movement disorders103.9 (2.1--7.2)5.5 (1.7--17.4)Eye disorders Lacrimation disorders62.4 (1.1--5.3)1.1 (0.4--2.9)Eye disorders Panniculitides54.8 (2.0--11.8)^a^Skin and subcutaneous disordersOmalizumab Neurological signs and symptoms NEC381.6 (1.2--2.2)2.7 (1.9--3.8)Nervous system disorders Feelings and sensations NEC272.5 (1.7--3.6)2.5 (1.6--3.8)Nervous system disorders Visual disorders NEC112.0 (1.1--3.6)2.0 (1.1--3.9)Eye disorders Speech and language abnormalities92.2 (1.1--4.1)2.1 (1.0--4.3)Nervous system disorders Exfoliative conditions63.1 (1.4--7.0)3.5 (1.4--8.8)Skin and subcutaneous disorders Sensory abnormalities NEC52.7 (1.1--6.5)2.4 (0.9--6.5)Nervous system disorders Oral soft tissue pain and paraesthesia56.7 (2.8--16.3)4.6 (1.6--13.5)Gastrointestinal disordersSalbutamol, inhaled Non-site specific vascular disorders NEC93.9 (2.0--7.5)4.8 (2.0--11.4)Vascular disorders Psychotic disorder NEC83.3 (1.6--6.6)1.2 (0.6--2.5)Psychiatric disordersSalbutamol, systemic Psychotic disorder NEC84.6 (2.3--9.2)1.7 (0.8--3.6)Psychiatric disorders Non-site specific vascular disorders NEC63.6 (1.6--8.1)3.8 (1.5--9.7)Vascular disordersSalmeterol + fluticasone Visual disorders NEC102.2 (1.2--4.2)2.3 (1.2--4.4)Eye disorders Increased intracranial pressure disorders94.3 (2.2--8.2)4.1 (1.9--8.8)Nervous system disorders Confusion and disorientation72.2 (1.0--4.5)1.7 (0.8--3.8)Psychiatric disorders Hypoglycaemic conditions NEC72.9(1.4--6.0)2.7 (1.2--6.1)Metabolism and nutrition disorders Tic disorders65.7 (2.6--12.7)2.1 (0.9--5.0)Psychiatric disorders Memory loss (excluding dementia)53.1 (1.3--7.4)2.1 (0.8--5.5)Nervous system disordersTheophylline Encephalopathies NEC69.8 (4.5--21.4)212.9 (43.5--1041.5)Nervous system disorders Abnormal behaviour NEC54.9 (2.1--11.6)1.2 (0.5--2.9)Psychiatric disorders*CI* confidence interval, *HLT* high-level term, *NEC* not elsewhere classified, *PRR-TA* proportional reporting ratio by therapeutic area, *SOC* system organ class^a^PRR-TA could not be calculated as the event was not reported in combination with other asthma drugs

Proportional Reporting Ratio by Therapeutic Area {#Sec9}
------------------------------------------------

The results of the PRR-TA differed from those of the overall PRR. Of all the signals, 126 disappeared when calculating the PRR-TA. This difference was most pronounced for 'respiratory, thoracic and mediastinal' disorders, as half of these signals disappeared when calculating the PRR-TA. On the other hand, the overall PRR of 38 DECs did not meet the definition of a safety signal, whereas the PRR-TA did show a signal. Three of these safety signals were new: omalizumab with 'bacterial infections NEC \[not elsewhere classified\]' and both omalizumab and budesonide with 'herpes viral infections' (Table [5](#Tab5){ref-type="table"}).Table 5New signals unmasked by PRR-TADrugReaction HLTReports (N)PRR (95% CI)PRR-TA (95% CI)BudesonideHerpes viral infections91.0 (0.5--1.9)7.7 (3.3--17.9)OmalizumabHerpes viral infections80.8 (0.4--1.5)5.3 (2.2--12.5)OmalizumabBacterial infections NEC60.8 (0.4--1.8)13.8 (3.9--48.9)*CI* confidence interval, *HLT* high-level term, *NEC* not elsewhere classified, *PRR-TA* proportional reporting ratio by therapeutic area

Children Versus All Ages {#Sec10}
------------------------

Of the 385 signals in children, 60 (16%) DECs no longer met the criteria of a signal when calculating the PRR in the whole dataset including all ages (both children and adults). All signals in children concerning the SOC 'respiratory, thoracic and mediastinal disorders' remained in the dataset that included children and adults together. In contrast, only 35 of the 50 signals in children concerning 'psychiatric disorders' remained in the whole dataset (Fig. [1](#Fig1){ref-type="fig"}).

Stratification by Age {#Sec11}
---------------------

Of all asthma medication-related DECs in children, 4429 (21%) pertained to children aged 0--2 years, 11,319 (53%) to children aged 3--11 years and 5516 (26%) to children aged 12--17 years. Upon stratification by age, 42 additional safety signals appeared: 16 of these were in the age category 0--2 years, 14 in the category 3--11 years and 12 in the category 12--17 years. These safety signals concerned 'pregnancy, puerperium and perinatal disorders' for events referring to in utero exposure and 'general disorders and administration site conditions', 'gastrointestinal disorders', 'psychiatric disorders' and 'nervous system disorders'. Six (14%) of the signals that only appeared upon age stratification were classified as new (Table [6](#Tab6){ref-type="table"}).Table 6New signals unmasked by stratification for ageDrugReaction HLTOverall PRR (95% CI)Age group, yearsReports in age groupPRR in age group (95% CI)Salbutamol, inhaledPerception disturbances1.5 (0.9--2.6)0--2614.8 (6.6--33.0)Salbutamol, inhaledCardiac septal defects congenital2.0 (0.8--4.7)0--252.8 (1.2--6.6)BudesonideNeutropenias1.8 (1.0--3.3)0--253.6 (1.5--8.5)TheophyllineFebrile disorders1.1 (0.7--1.7)3--11132.3 (1.4--3.6)MontelukastDiabetes mellitus (including subtypes)1.6 (0.9--3.0)3--11112.3 (1.3--4.2)OmalizumabCardiac signs and symptoms NEC1.2 (0.7--2.1)3--1152.8 (1.2--6.6)MontelukastGastrointestinal atonic and hypomotility disorders NEC1.2 (0.7--2.1)12--1752.8 (1.2--6.6)*CI* confidence interval, *HLT* high-level term, *NEC* not elsewhere classified, *PRR* proportional reporting ratio

Stratification by Sex {#Sec12}
---------------------

The sex of the patient was known in 20,726 DECs (98%), with 11,926 (56%) DECs concerning boys and 8800 (41%) concerning girls. Upon sex stratification, 289 (77%) signals remained. On the other hand, 30 DECs additionally met the definition of a safety signal, four of which (two each in males/females) were classified as new (Table [7](#Tab7){ref-type="table"}). More signals appeared in boys only (97 signals) than in girls only (35 signals). Signals more often appeared in boys than in girls for 'psychiatric disorders', 'musculoskeletal and connective tissue disorders' and 'eye disorders', whereas they appeared more often in girls for 'cardiac disorders' (Fig. [2](#Fig2){ref-type="fig"}).Table 7New signals unmasked by stratification for sexDrugReaction HLTOverall PRR (95% CI)SexReportsPRR-sex (95% CI)FluticasoneAppetite disorders1.5 (0.9--2.8)Female72.5 (1.2--5.1)MontelukastAlopecias1.5 (0.8--2.8)Male62.9 (1.3--6.5)MontelukastFlatulence, bloating and distension1.3 (0.7--2.5)Female62.5 (1.1--5.5)OmalizumabLid, lash and lacrimal infections, irritations and inflammations1.9 (0.8--4.5)Male53.5 (1.5--8.5)*CI* confidence interval, *HLT* high-level term, *NEC* not elsewhere classified, *PRR* proportional reporting ratioFig. 2Signals after stratification by sex categorized as a signal in boys only, girls only or both sexes

Discussion {#Sec13}
==========

In this study, we investigated spontaneous reports of adverse events related to asthma drugs in children. We were able to include fivefold more reports than a previous analysis of EudraVigilance data from 2007 to 2011 \[[@CR20]\]. We observed that spontaneous reports for montelukast were the most frequent, followed by reports for salbutamol, omalizumab and budesonide. Although 92% of the statistical signals were already known, we observed 30 new signals, especially for omalizumab. Calculation of the PRR by therapeutic area, age and sex revealed additional new signals, pointing to masking due to confounding by indication or effect modification.

Safety signals of asthma drugs were mainly related to psychiatric disorders, especially in combination with the use of montelukast. This is in line with a recent review that concluded that LTRAs are frequently associated with neuropsychiatric adverse events \[[@CR6]\]. Awareness of the potential for psychiatric adverse events when initiating treatment with asthma drugs is important so that stopping treatment may be considered when the first symptoms of psychiatric events are observed. The second largest group of safety signals, 'respiratory, thoracic and mediastinal disorders', is of course prone to confounding by indication. This is further supported by our observation that half of the signals from this group disappeared when we calculated the PRR-TA.

Some observed new signals were already reported in the literature but not included in the SmPC, Martindale and UpToDate. For example, a study of spontaneous reports from Lareb, The Netherlands Pharmacovigilance Centre \[[@CR33]\] associated hypertrichosis, both statistically and through causality assessment, with ICS, and cases of acute encephalopathies have been described with theophylline use. Although seizures are already listed as adverse reactions in the SmPC of theophylline, multiple cases of post-ictal coma lasting \> 24 h have been described, regarding it as acute encephalopathy instead of a mere seizure \[[@CR34]\]. We also found 'herpes viral infections' as a new signal associated with omalizumab. An increase in oral herpes in patients using omalizumab, without reaching statistical significance, has been mentioned in the literature \[[@CR35]\]. One case of herpes labialis has been described in the literature, with the timing of herpes relapses directly related to omalizumab treatment \[[@CR36]\]. Further studies should be conducted to confirm these new safety signals and investigate possible mechanisms.

Omalizumab, a monoclonal anti-IgE antibody, has been authorized in Europe since 2005. It is prescribed by specialist physicians to patients with asthma and IgE-mediated allergy that is difficult to control. Our results indicated new safety signals for omalizumab, including herpes viral infections, bacterial infections and visual disorders. The indication of use---namely, severe allergic asthma---implies that these patients were treated not only with omalizumab but also with other asthma drugs, especially high-dose ICS and systemic corticosteroids, both of which have immunosuppressive effects. Omalizumab is a systemic drug administered via intramuscular injection instead of inhaler therapy, which could also explain the relatively high number of reports.

We showed that many safety signals in children did not meet the criteria of a signal when calculating the PRR in the whole dataset that included adults. This means that such signals would have been missed had we not examined spontaneous reports in children separately. We also observed the importance of stratification for age within the paediatric group. Studies have demonstrated that stratification for age may unmask signals but adjustment for age does not improve the analyses \[[@CR37], [@CR38]\]. This emphasises the importance of actively monitoring the safety of drugs in children. When stratifying by sex, most signals remained. The prevalence of asthma, and thus the use of asthma drugs, is higher in boys than in girls. This may explain why more signals were reported for boys than for girls, as at least five reports are required for a signal \[[@CR39]\].

The strength of our study lies in our use of one of the largest databases of spontaneous reports and data from many different countries, covering a heterogeneous paediatric population. This provided us with the opportunity to study the safety of a drug in real life and to report on signals of a relatively new drug, omalizumab. It also allowed us to stratify for age and sex. Spontaneous reports remain the most important source of detecting (new) safety signals, but the use and interpretation of these data has some limitations \[[@CR14]\]. First, underreporting is likely in spontaneous report databases, and the adverse events that are reported are only the tip of the iceberg \[[@CR40]\]. Another challenge of this type of study is that the MedDRA terms do not always match exactly the adverse reactions as mentioned in the SmPC and literature. This makes it difficult to interpret whether a signal is an already known adverse reaction. Reports might consist of a combination of multiple events and multiple drugs, and we were unable to deduct which was the culprit drug from these data, even though we only included those that were reported as suspected or interacting. Additional information from the report, such as the complete narrative, might have given more insight; unfortunately, data protection regulations meant these were unavailable. Also, some events were not reported frequently. This resulted in wide CIs, which require careful interpretation of the PRR. Finally, although we did have different combinations of medication and drugs, we did not have the number of reports containing a certain event combined with at least one type of asthma medication. This may have led to an underestimation of the true PRR-TA as the denominator was the number of combinations between the event and all asthma drugs.

For pharmacovigilance, it is paramount that any new suspected adverse drug reactions are reported immediately and include important details such as age and sex. This reporting is facilitated via online submission through the EudraVigilance website \[[@CR41]\]. EudraVigilance also provides healthcare professionals with a graphical overview of the type of reported adverse drug reactions (by age, sex, type of reporter and outcome) of all centrally authorised drugs.

Conclusion {#Sec14}
==========

We characterized spontaneous reports of asthma drugs in children. We again showed the importance of investigating adverse events in children separately from adults and in different age and sex strata. We identified new signals that need to be further followed-up to investigate the true associations and causality.
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